Figure 6.

Early treatment with probenecid or AZ11645373 results in improved efficacy. Groups of C57BL/6 mice were infected intranasally with (a, c) 10⁵ PFU of HKx31 or (b, d) 50 PFU of PR8 (n = 8 per group). Mice were treated intranasally with probenecid (40 mg kg⁻¹), AZ11645373 (20 mg kg⁻¹), or PBS commencing prior to the induction of severe disease (day 1 HKx31 or day 5 PR8) and every 48 hr thereafter (arrows). (a, b) Mice were weighed daily, and results are expressed as mean per cent weight change ± SEM. (c, d) Survival curves are shown. *P < .05 PBS, significantly different from AZ11645373; ^# P < .05, PBS significantly different from probenecid; Mantel–Cox log‐rank test